Search research articles
Contact Us
Filters
Showing results (111-120 of 209) with videos related to
Page
of 21
Sort By:
The Lancet. Oncology
|
January 30, 2017
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, et al.
Journal for Immunotherapy of Cancer
|
April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
The Oncologist
|
February 8, 2019
Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer
Chelsea K Osterman, Dilip S Babu, Daniel M Geynisman, et al.
Journal for Immunotherapy of Cancer
|
October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer
|
March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Clinical Genitourinary Cancer
|
October 8, 2018
Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Andrea Necchi, Gregory R Pond, Marco Moschini, et al.
Urologic Oncology
|
June 17, 2014
Micropapillary bladder cancer: current treatment patterns and review of the literature
Daniel L Willis, Thomas W Flaig, Donna E Hansel, et al.
European Urology Oncology
|
July 10, 2021
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial
Brian I Rini, Michael B Atkins, Elizabeth R Plimack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J Motzer, Brian I Rini, David F McDermott, et al.
Page
of 21
Search research articles
Search
Showing results (111-120 of 209) with videos related to
Sort By:
Page
of 21
The Lancet. Oncology
|
January 30, 2017
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, et al.
Journal for Immunotherapy of Cancer
|
April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
The Oncologist
|
February 8, 2019
Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer
Chelsea K Osterman, Dilip S Babu, Daniel M Geynisman, et al.
Journal for Immunotherapy of Cancer
|
October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer
|
March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Clinical Genitourinary Cancer
|
October 8, 2018
Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Andrea Necchi, Gregory R Pond, Marco Moschini, et al.
Urologic Oncology
|
June 17, 2014
Micropapillary bladder cancer: current treatment patterns and review of the literature
Daniel L Willis, Thomas W Flaig, Donna E Hansel, et al.
European Urology Oncology
|
July 10, 2021
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial
Brian I Rini, Michael B Atkins, Elizabeth R Plimack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J Motzer, Brian I Rini, David F McDermott, et al.
Page
of 21